Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study

[1]  N. McHugh,et al.  Autoantibodies in myositis , 2018, Nature Reviews Rheumatology.

[2]  L. Pachman,et al.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. , 2018, The Journal of pediatrics.

[3]  I. Kondratenko,et al.  Recent thymic emigrants, T regulatory cells, and BAFF level in children with X-linked agammaglobulinaemia in association with chronic respiratory disease. , 2018, Allergologia et immunopathologia.

[4]  Publisher's Note , 2018, Anaesthesia.

[5]  C. Oddis,et al.  Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab , 2017, Rheumatology.

[6]  B. Grimbacher,et al.  Defects in B Cell Survival and Activation , 2016 .

[7]  I. Kobayashi,et al.  Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis , 2015, The Journal of Rheumatology.

[8]  Andriy I. Bandos,et al.  Predictors of Clinical Improvement in Rituximab‐Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis , 2014, Arthritis & rheumatology.

[9]  H. Rockette,et al.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. , 2013, Arthritis and rheumatism.

[10]  K. Takehara,et al.  Accumulation of mature B cells in the inflamed muscle tissue of a patient with anti-155/140 antibody-positive juvenile dermatomyositis , 2013, Modern rheumatology.

[11]  F. Naeim.  Atlas of hematopathology : morphology, immunophenotype, cytogenetics, and molecular approaches , 2013 .

[12]  M. van der Burg,et al.  Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion , 2007, The Journal of experimental medicine.

[13]  C. Perry,et al.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. , 2006, Drugs.

[14]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[15]  R. Bode,et al.  Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. , 2003, Arthritis and rheumatism.

[16]  D. Figgitt,et al.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. , 2003, Drugs.